Trials / Completed
CompletedNCT04857437
Study in Healthy Adults Evaluating PF-07202954
A PHASE 1, 3-PART, SPONSOR OPEN STUDY OF PF-07202954 IN HEALTHY ADULTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE (IN PART 1), AND REPEATED (IN PART 2), ESCALATING, ORAL DOSES ALONG WITH CONDITIONAL PART 3 OF RANDOMIZED, OPEN-LABEL ASSESSMENT OF EFFECT OF FOOD ON PF-07202954 EXPOSURE
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07202954 Repeat Dose | 10, 30, 100, 300, 600, 1200 milligrams (mg) |
| DRUG | PF-07202954 Single Dose | 10, 30, 100, 300, 600, 900, 1200 milligrams (mg) |
| DRUG | Placebo | Matching Placebo |
Timeline
- Start date
- 2021-05-13
- Primary completion
- 2021-09-17
- Completion
- 2021-09-17
- First posted
- 2021-04-23
- Last updated
- 2024-09-20
- Results posted
- 2024-09-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04857437. Inclusion in this directory is not an endorsement.